<DOC>
	<DOC>NCT01213667</DOC>
	<brief_summary>To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.</brief_summary>
	<brief_title>Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>active subfoveal CNV related to exudative agerelated macular degeneration (all subforms) age &gt; 60 years visual acuity &gt; 20/400 no previous treatment for AMD any previous AMD therapy other CNV types (myopic, parapapillary) contraindication for ranibizumab treatment prior study participation for AMD pregnancy / premenopausal women</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>